On Wednesday May 8 at 09:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q1 2024 report (which will have been published earlier on May 8 at 07.30 a.m. CET).…
Devyser has received IVDR approval for Advyser Solid organs, its software for the post-transplant product One Lambda Devyser Accept cfDNA. This is Devyser’s first European approval for…
Devyser Diagnostics AB announces today it has entered into a co-marketing agreement with Hamilton Bonaduz AG, a leading global manufacturer of laboratory automation technology.
The…
Devyser Diagnostics AB announces today that it has received Medical Device Single Audit Program (MDSAP) certification for its quality management system (QMS) for both Devyser assays and…
Devyser´s annual report 2023 has today been published on the company´s website. The report is available on: https://investors.devyser.com/en/reports-presentations The financial year…
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is valid for a period of up to four years. Indicative order value is estimated to be…
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA (dd-cfDNA) in the setting of multiple kidney transplantations” was published in the…
“Devyser is able to report strong sales growth and record high gross margins for the fourth quarter. During the quarter, Devyser continued to demonstrate the competitiveness of its…
On Tuesday February 20 at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q4 2023 report (which will have been published earlier on February 20 at 07.30 CET).…
Devyser is today announcing the strengthening and expanding of its management team as of February 1, 2024. Michael Uhlin, who has been Devyser’s CSO since the fall of 2023, will join the…
